US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 14 November 2019

Today, on 14 November 2019, an annual general meeting was held in Ascelia Pharma AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.Resolution on adoption of accounts and allocation of the company's resultThe annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved in accordance with the proposal from the board of directors to allocate the company's result, meaning that no dividends are

Ascelia Pharma to present at Redeye seminar in Malmö on 12 September 2019

On 12th of September, Ascelia Pharma’s CEO Magnus Corfitzen will present the latest development in the company at Redeye’s afterwork event in Malmö. The presentation will be held at Clarion Hotel & Congress Malmö Live and Ascelia Pharma will start its presentation at 6pm CET.The presentation can also be followed live via: https://www.redeye.se/live/inv-aw-malmo-12-9 Program and registration for the event can be found here: https://www.redeye.se/events#/event/583611 For more information, please contact:Mikael Widell, IR & Communications ManagerEmail: mw@ascelia.comTel: +46 703 11

Ascelia Pharma to present at Share Day (Aktiedagen) in Stockholm on 10 September 2019

On 10th of September, Ascelia Pharma's CEO Magnus Corfitzen will present the latest development in the company at Operaterassen in Stockholm. The Share Day event (Aktiedagen) is organised by Swedish Shareholders' Association and Ascelia Pharma will start the presentation at 8.30am CET.The presentation can be followed live via: www.aktiespararna.se/tv/live  Program and registration for the day can be found here: https://www.aktiespararna.se/aktiviteter/aktiedagen-stockholm-4 For more information, please contact:Mikael Widell, IR & Communications

Phase III study of Mangoral to start in H2-2019

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its full-year report for the period July 2018 - June 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN Q4 (APRIL-JUNE 2019) · Encouraging results from Oncoral’s Phase I combination study with oral capecitabine · Supportive feedback from EMA on the Phase III program for Mangoral · New patent application filed for Mangoral with potential to extend IP rights to year 2040 · IPO overallotment utilised raising SEK 22 million FINANCIAL SUMMARY IN Q4 (

Invitation to presentation of Ascelia Pharma’s Q4 report 2018/2019

Ascelia Pharma’s full-year report for the period July 2018 – June 2019 (FY 2018/2019) will be published on Thursday 22 August 2019 at 09:00 CET. A presentation for analysts, media and investors will be held the same day at 09:00 CET.The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos and CMO Carl Bjartmar. The presentation will be held in English.  The presentation can be followed live via the link:https://tv.streamfabriken.com/ascelia-pharma-q4-2018-2019  It will also be possible to take part of the audiocast afterwards at the same address or at

Ascelia Pharma strengthens its Mangoral franchise by filing of a patent application for next generation Mangoral product

Today, Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia”) announces that it has filed a patent application for a next generation Mangoral product. Upon grant, the new patent would further improve the unique value proposition of Mangoral and extend the intellectual property protection rights until year 2040.Ascelia’s lead imaging drug Mangoral is covered by an Orphan Drug Designation in the US, providing 7 to 7.5 years of market exclusivity after its marketing authorization approval, and in EU/EEA, data exclusivity can prevail from up to 10 years after marketing authorization. With the

Ascelia Pharma to present at Avanza börsdag, 22 May 2019

On 22 May 2019, Ascelia Pharma’s CEO Magnus Corfitzen will present at the Avanza share seminar (“börsdag”). The presentation will be held at Operaterassen in Stockholm. Ascelia Pharma’s presentation starts at 9:45am CET and will also be broadcasted live as a webcast: https://tv.streamfabriken.com/2019-05-22-ascelia-pharmaTo register for the seminar, please visit: https://financialhearings.com/event/11336 The presentation will also be available on Ascelia Pharma’s website after the seminar via the links found above. For more information, please contactMikael Widell, IR &

Fully financed Phase III program for Mangoral through the IPO

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its interim report for the period January-March 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/IMPORTANT EVENTS IN THE PERIOD · IPO of SEK 200 million · More than 6,000 new shareholders in the IPO – both institutional and private · Fully financed Phase III program for Mangoral IMPORTANT EVENTS AFTER THE PERIOD · Encouraging results from Oncoral’s Phase I combination study with oral capecitabine · IPO overallotment utilised raising SEK 22 million ·

Ascelia Pharma to host teleconference for presentation of interim financial report

Ascelia Pharma’s interim report for the period January – March 2019 (Q3 2018/2019) will be published on Wednesday 15 May 2019 at 08:00 CET. A presentation for analysts, media and investors will be held the same day at 10:00 CET.The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos and CMO Carl Bjartmar. The presentation will be held in English. The presentation can be followed live via the link:https://tv.streamfabriken.com/ascelia-pharma-q3-2018-2019 It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia

Nomination Committee appointed for AGM 2019 in Ascelia Pharma AB

Ascelia Pharma AB (publ) (ticker: ACE) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on 14 November 2019 has been appointedAccording to the instruction for Nomination Committee in Ascelia Pharma AB (publ) adopted at the annual general meeting held on 23 November 2018, the Nomination Committee shall consist of four members, representing the three largest shareholders per the end of March, together with the chairman of the board of directors. The “three largest shareholders” refer to the ownership grouped registered or in any other way known

Ascelia Pharma received supportive feedback from EMA on the phase 3 program for Mangoral®

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the company has completed constructive discussions with the European Medicines Agency (EMA) regarding the clinical development program for Mangoral® as a contrast agent in patients with focal liver lesions and severe renal impairment. Ascelia Pharma will now finalise preparations for the clinical Phase 3 study and expects to enrol the first patient during the second half of 2019.Mangoral is an oral contrast agent for liver MRI developed to facilitate the visualisation of focal liver lesions, including liver metastases, using

Change in number of shares and votes in Ascelia Pharma AB (publ)

During April, the registered number of shares and votes in Ascelia Pharma AB (publ) has increased due to the new issue that was executed in connection with the exercise of the over-allotment option subsequent to the listing of the company’s shares on Nasdaq Stockholm. As of 30 April 2019, the registered number of shares and votes in Ascelia Pharma AB (publ) amounts to 23,488,908.For more information, please contactMagnus Corfitzen, CEOEmail: moc@ascelia.comTel: +46 735 179 110 Mikael Widell, IR & Communications ManagerEmail: mw@ascelia.comTel: +46 703 11 99 60This information

Exercise of over-allotment option, stabilisation notice and end of the stabilisation period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Company”) shares on Nasdaq Stockholm, that Erik Penser Bank exercises the over-allotment option regarding 882,017 shares in Ascelia Pharma and that the stabilization

Stabilisation notice

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Company”) shares on Nasdaq StockholmAs announced in connection with the offering to acquire newly issued shares in the Company and the listing of the Company’s

Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology

Ascelia Pharma AB (ticker: ACE), announces results from the Phase I investigator-sponsored extension study (ClinicalTrials.gov Identifier: NCT03295084) demonstrating reassuring tolerability of the oral chemotherapy tablet Oncoral (oral irinotecan) administered in combination with oral capecitabine. These results are published in Cancer Chemotherapy and Pharmacology, a peer reviewed medical journal covering oncological pharmacotherapy.The Phase I study for Oncoral consisted of two parts. The first, where Oncoral was given as a single agent, was published last fall showing promising results.

Stabilisation notice

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Company”) shares on Nasdaq Stockholm.As announced in connection with the offering to acquire newly issued shares in the Company and the listing of the Company’s

Change in number of shares and votes in Ascelia Pharma AB (publ)

During March, the registered number of shares and votes in Ascelia Pharma AB (publ) has increased due to the new issue that was executed in connection with the listing of the company’s shares on Nasdaq Stockholm. As of 29 March 2019, the registered number of shares and votes in Ascelia Pharma AB (publ) amounts to 22,606,891.For more information, please contactMagnus Corfitzen, CEOEmail: moc@ascelia.comTel: +46 735 179 110 Mikael Widell, IR & Communications ManagerEmail: mw@ascelia.comTel: +46 703 11 99 60This information is such information as Ascelia Pharma AB (publ) is

Stabilisation notice

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Company”) shares on Nasdaq Stockholm.As announced in connection with the offering to acquire newly issued shares in the Company and the listing of the Company’s

Trading in Ascelia Pharma’s shares on Nasdaq Stockholm commences tomorrow

Nasdaq Stockholm AB has today decided to admit the shares of Ascelia Pharma AB ("Ascelia Pharma" or the “Company") for trading on Nasdaq Stockholm with first day of trading tomorrow, Wednesday 13 March 2019. The shares will be traded under the ticker ACE and ISIN SE0010573113.The offering in Ascelia Pharma AB in connection with the listing on Nasdaq Stockholm was, as previously communicated, significantly oversubscribed. The offering provided Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the offering. The listing on Nasdaq Stockholm gives

Ascelia Pharma’s new share issue in connection with the IPO on Nasdaq Stockholm was significantly oversubscribed

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The offering in Ascelia Pharma AB ("Ascelia Pharma" or the “Company") in connection with the Initial Public Offering on Nasdaq Stockholm was significantly oversubscribed. The new share issue (the “Offering”) will provide Ascelia Pharma with approximately SEK 200 million before deductions for expenses related to the Offering.

Ascelia Pharma publishes prospectus in connection with Initial Public Offering on Nasdaq Stockholm

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Ascelia Pharma AB ("Ascelia Pharma" or the “Company") has decided to issue new shares to the general public in Sweden and Denmark as well as institutional investors in Sweden and abroad (the "Offering"). The Company's Board of Directors also intend to apply for admission to trading of the Company's shares on Nasdaq Stockholm

Ascelia Pharma receives positive feedback from FDA on design of the pivotal Phase 3 study with Mangoral®

Ascelia Pharma AB today announced that the company has successfully concluded discussions with the US Food and Drug Administration (FDA) regarding the study design for the single pivotal Phase 3 trial for Mangoral® as a contrast agent in patients with focal liver lesions and severe renal impairment.  Ascelia Pharma will now complete the preparatory work to start the trial and expects to enroll the first patient during the second half of 2019.Mangoral® is an oral contrast agent for liver MRI developed to facilitate the visualization of focal liver lesions, including liver metastases, using

Encouraging results from clinical Phase I study of Oncoral presented in a new publication

In continuation of the previously published poster presentation at ESMO in Munich, 19-23 October 2018, Ascelia Pharma has announced the encouraging Phase I results in a new publication titled Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.The publication, which is available on pubmed.gov , contains data from a dose escalation study in adult patients with solid tumors to assess safety, tolerability and pharmacokinetics of Oncoral,

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media